Why the study?
Mechanical heart valve prostheses increase thromboembolic risk and warfarin reduces this while increasing bleeding risk, prompting estimation of these complication rates and associated factors at a tertiary hospital in Botswana.
Answers are grounded in this paper and cite their sources.
Patients with mechanical heart valves in Botswana experience high rates of thromboembolic and bleeding complications, largely driven by poor anticoagulation control (median TTR 29.8%).
INTRODUCTION: Mechanical heart valve (MHV) prostheses increase the risk of thromboembolic complications. While warfarin anticoagulation reduces this risk, its use increases the risk of bleeding. We sought to estimate the rate of thromboembolic and bleeding complications among patients with MHVs at a tertiary hospital in Botswana. Factors associated with bleeding and thromboembolic complications are also described. METHODS: This retrospective cohort study involved a cohort of patients with MHV at Princess Marina Hospital who were operated on before September 2017. The study documented bleeding and thromboembolic events since the valve replacement, patients' demographic information, co-existing medical conditions, drug history and details of valve replacement. Using the recent international normalised ratio (INR) results, each patient's time in therapeutic range (TTR) was calculated to assess the level of anticoagulation control. CONCLUSIONS: Bleeding and thromboembolic complications were common in MHV prosthesis patients in this study. Long duration of anticoagulation, albeit sub-optimal control, was a risk factor for bleeding and thromboembolic complications in these patients. Therefore, long-term efforts are necessary to address these complications and possibly improve the quality of life of these patients.
No takes yet. Share an insight, caveat, or question.
Botsile et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: